Product Review – Sacubitril/Valsartan

This is a product review of the use of angiotensin receptor neprilysin inhibitor sacubitril/valsartan in patients with heart failure and reduced ejection fraction. This review discusses the evidence in support of the use of sacubitril/valsartan, its dosage, interactions, safety, and efficacy and tolerability demonstrated in pivotal clinical trials.

It also provides commentary and recommendations from Professor Andrew Sindone, Director of the Heart Failure Unit and Department of Cardiac Rehabilitation at Concord Hospital, and Consultant Cardiologist at Ryde Hospital in Sydney.

Please login below to download this issue (PDF)